| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 158.49% | Morgan Stanley | $38 → $35 | Maintains | Overweight |
| 11/08/2023 | 165.88% | Cantor Fitzgerald | $46 → $36 | Maintains | Overweight |
| 10/03/2023 | 276.66% | Mizuho | → $51 | Reiterates | Buy → Buy |
| 09/12/2023 | 239.73% | Cantor Fitzgerald | → $46 | Reiterates | Overweight → Overweight |
| 09/07/2023 | 239.73% | Cantor Fitzgerald | → $46 | Reiterates | Overweight → Overweight |
| 09/06/2023 | 269.28% | Truist Securities | → $50 | Reiterates | Buy → Buy |
| 09/05/2023 | 69.87% | B of A Securities | $21 → $23 | Maintains | Neutral |
| 08/24/2023 | 224.96% | Citigroup | $41 → $44 | Maintains | Buy |
| 08/23/2023 | 416.99% | BTIG | → $70 | Reiterates | Buy → Buy |
| 08/23/2023 | 276.66% | Mizuho | → $51 | Reiterates | Buy → Buy |
| 08/08/2023 | 180.65% | Morgan Stanley | $40 → $38 | Maintains | Overweight |
| 07/12/2023 | 239.73% | Cantor Fitzgerald | → $46 | Reinstates | Overweight → Overweight |
| 05/26/2023 | 202.81% | Citigroup | $40 → $41 | Maintains | Buy |
| 05/10/2023 | 165.88% | Wedbush | → $36 | Reiterates | → Outperform |
| 03/17/2023 | 276.66% | Mizuho | → $51 | Reiterates | → Buy |
| 03/08/2023 | 195.42% | Citigroup | $42 → $40 | Maintains | Buy |
| 12/21/2022 | 158.49% | Barclays | $60 → $35 | Maintains | Overweight |
| 12/20/2022 | 210.19% | Citigroup | $37 → $42 | Maintains | Buy |
| 11/23/2022 | 173.26% | Citigroup | $40 → $37 | Maintains | Buy |
| 11/18/2022 | 143.72% | B of A Securities | → $33 | Initiates Coverage On | → Neutral |
| 11/03/2022 | 180.65% | SVB Leerink | $40 → $38 | Maintains | Outperform |
| 10/11/2022 | 195.42% | Morgan Stanley | → $40 | Initiates Coverage On | → Overweight |
| 08/18/2022 | 195.42% | Citigroup | $48 → $40 | Maintains | Buy |
| 08/04/2022 | 261.89% | SVB Leerink | $66 → $49 | Maintains | Outperform |
| 07/08/2022 | 269.28% | Truist Securities | $77 → $50 | Maintains | Buy |
| 05/12/2022 | 106.79% | Goldman Sachs | $48 → $28 | Maintains | Neutral |
| 05/11/2022 | 254.51% | Goldman Sachs | $43 → $48 | Maintains | Neutral |
| 11/19/2021 | 291.43% | Citigroup | $42 → $53 | Maintains | Buy |
| 11/19/2021 | 343.13% | Barclays | $48 → $60 | Maintains | Overweight |
| 11/18/2021 | 638.55% | SVB Leerink | $68 → $100 | Maintains | Outperform |
| 11/09/2021 | 254.51% | Barclays | $45 → $48 | Maintains | Overweight |
| 08/06/2021 | 402.22% | SVB Leerink | $63 → $68 | Maintains | Outperform |
| 06/24/2021 | 365.29% | SVB Leerink | $53 → $63 | Maintains | Outperform |
| 02/25/2021 | 291.43% | SVB Leerink | $54 → $53 | Maintains | Outperform |
| 01/26/2021 | 298.82% | SVB Leerink | $41 → $54 | Maintains | Outperform |
| 11/24/2020 | 269.28% | Berenberg | → $50 | Initiates Coverage On | → Buy |
| 11/23/2020 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 11/06/2020 | 202.81% | SVB Leerink | $44 → $41 | Maintains | Outperform |
| 08/10/2020 | 224.96% | SVB Leerink | $42 → $44 | Maintains | Outperform |
| 05/29/2020 | 210.19% | SVB Leerink | $21 → $42 | Reiterates | → Outperform |
| 05/14/2020 | 195.42% | Mizuho | $22 → $40 | Maintains | Buy |
| 04/03/2020 | 55.1% | Cantor Fitzgerald | → $21 | Initiates Coverage On | → Overweight |
| 04/01/2020 | 62.48% | SunTrust Robinson Humphrey | $20 → $22 | Maintains | Buy |
| 03/04/2020 | 77.25% | Barclays | → $24 | Initiates Coverage On | → Overweight |
| 11/12/2019 | 47.71% | SunTrust Robinson Humphrey | → $20 | Initiates Coverage On | → Buy |
| 09/27/2019 | 62.48% | Mizuho | → $22 | Initiates Coverage On | → Buy |
| 05/24/2019 | 84.64% | Citigroup | → $25 | Assumes | → Buy |
| 03/18/2019 | 47.71% | BTIG | → $20 | Initiates Coverage On | → Buy |
What is the target price for Arcus Biosciences (RCUS)?
The latest price target for Arcus Biosciences (NYSE: RCUS) was reported by Morgan Stanley on November 13, 2023. The analyst firm set a price target for $35.00 expecting RCUS to rise to within 12 months (a possible 158.49% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Arcus Biosciences (RCUS)?
The latest analyst rating for Arcus Biosciences (NYSE: RCUS) was provided by Morgan Stanley, and Arcus Biosciences maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Arcus Biosciences (RCUS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arcus Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arcus Biosciences was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
Is the Analyst Rating Arcus Biosciences (RCUS) correct?
While ratings are subjective and will change, the latest Arcus Biosciences (RCUS) rating was a maintained with a price target of $38.00 to $35.00. The current price Arcus Biosciences (RCUS) is trading at is $13.54, which is out of the analyst's predicted range.